ClinicalTrials.gg
CompletedNCT02660684Updated Mar 1, 2016

Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor

A Phase 4 interventional study of Prograf and Methotrexate in Graft Versus Host Disease, sponsored by Astellas Pharma Korea, Inc.. Completed at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-01.

Sponsored by Astellas Pharma Korea, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing tacrolimus in Graft vs Host Disease — 3 open to participants now, 4 under way, none of them phase 3. Tacrolimus · Graft vs Host Disease.

Enrollment
15th of 32
39 · median 34
Started
2008
with 1 other
Phase 4
3 of 36
none open now
Registered
31st of 36
by date
Lead sponsor
1 of 36
Astellas Pharma Korea, Inc.

Among the 36 studies testing tacrolimus in Graft vs Host Disease, this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2008, is one of 3 in phase 4, and was the 31st registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

3 of the 36 studies testing tacrolimus in Graft vs Host Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing tacrolimus in Graft vs Host Disease, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and efficacy of Tacrolimus (Prograf capsule, Prograf injection) and Methotrexate combination therapy for GVHD prophylaxis in patients who received peripheral hematopoietic stem cell transplantation from a sibling donor, and to compare with data from a historical control group that administered a conventional Cyclosporine formulation.

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

Keywords

  • Prograf
  • Graft versus host disease
  • Hematopoietic stem cell transplantation
  • Prophylaxis
  • Peripheral hematopoietic stem cell transplantation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Blood diseases for a standard risk group

    • Primary remission of AML (acute myeloid leukemia)
    • Primary remission of ALL (acute lymphocytic leukemia)
    • Secondary remission of ALL (acute lymphocytic leukemia)
    • SAA (severe aplastic anemia)
    • Chronic stage CML (chronic myeloid leukemia)
    • MDS (myelodysplastic syndrome)
    • Myeloma (multiple myeloma)
  • A patient who received peripheral hematopoietic stem cell transplantation from a HLA-matched sibling donor

Exclusion criteria

Exclusion Criteria:

  • A patient with renal impairment (serum creatinine level ≥ 1.5mg/dl or 130μmol/l, ≤ 30%)
  • A pregnant or breastfeeding woman
  • A woman who is unwilling or unable to practice appropriate during the study
  • A patient who is highly likely to experience aggravation during treatment due to active tuberculosis, other hepatic disease, hypertension, heart failure, chronic obstructive respiratory disease, etc.
  • A patient with to tacrolimus
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Prograf + MTX

    Drug: Prograf · Drug: Methotrexate

  • Active comparator
    Cyclosporine + MTX (historical control)

    Drug: Methotrexate · Drug: Cyclosporine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of occurrence sites of acute GVHD occurring within 100 days after peripheral hematopoietic stem cell transplantation from a sibling donor

    Time frame: Day 1 up to Day 100 post-transplant

  2. Severity of acute GVHD occurring within 100 days after peripheral hematopoietic stem cell transplantation from a sibling donor

    Severity is graded according to the Seattle criteria, between 1+ \~ 4+ depending on the severity of the injury of the skin, liver and digestive system, and the overall grade is classified by including the performance change.

    Time frame: Day 1 up to Day 100 post-transplant

  3. Number of occurrence sites of chronic GVHD occurring after 100 days after peripheral hematopoietic stem cell transplantation from a sibling donor

    Time frame: Day 100 up to 1 year post-transplant

  4. Classification of chronic GVHD occurring after 100 days after peripheral hematopoietic stem cell transplantation from a sibling donor

    Depending on the extent of occurrence, it is classified as limited (present only locally) and extensive (systemic lesions). Depending on the presence of preceding acute GVHD, it is classified as progressive for a patient with preceding acute GVHD (chronic GVHD following the occurrence of acute GVHD), quiescent (chronic GVHD after relief of acute GVHD symptoms) or otherwise (de novo).

    Time frame: Day 100 up to 1 year post-transplant

  5. Safety as assessed by adverse events

    Time frame: Day 1 up to 1 year post-transplant

  6. Safety as assessed by laboratory assessments

    Includes hematology, biochemistry and trough plasma concentration analysis

    Time frame: Day 1 up to 1 year post-transplant

Secondary outcomes

  1. Percentage of patients alive after peripheral hematopoietic stem cell transplantation from a sibling donor

    Time frame: Day 1 up to 1 year post-transplant

  2. Percentage of patients alive after peripheral hematopoietic stem cell transplantation from a sibling donor in comparison with Cyclosporine in combination with MTX

    Time frame: Day 1 up to 1 year post-transplant

07

Study locations

3 sites
  • Daegu, Gyeongsangnam-do, Korea, Republic of
  • Hwasun-gun, Jeonranam-do, Korea, Republic of
  • Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2016
First posted
Jan 21, 2016
Start
Feb 2008
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Last update
Mar 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02660684
Responsible party
Sponsor
First posted
Jan 21, 2016
Start date
Feb 2008
Primary completion
Feb 2010
Completion
Feb 2010
Last update
Mar 1, 2016

Study contacts

Medical Director
study director · Astellas Pharma Korea, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion